About

Leading the way to new therapies for MPNs and other hematological diseases and cancers


At PharmaEssentia, we are building a fully integrated,

global biopharmaceutical company with the goal of becoming a leader

in treating myeloproliferative neoplasms (MPNs) and other cancers.

About PharmaEssentia

PharmaEssentia Corporation (TWSE : 6446) is a fully integrated global biopharmaceutical company delivering efficacious, safe and cost-effective therapeutic products for the treatment of human diseases while aiming to bring long lasting value to stakeholders.


PharmaEssentia was founded in 2003 by a group of Taiwanese-American executives and high-ranking scientists from leading U.S. biotechnology and pharmaceutical companies in order to develop treatments for myeloproliferative neoplasms, hepatitis and other diseases. The company is committed to the improvement of health and quality of life for patients suffering from these diseases.


The Company's world-class cGMP biologics facility in Taichung is certified by the Taiwan Food and Drug Administration (TFDA) and is designed and operated to be compliant with all U.S. FDA and EMA requirements.

Mission

We build on our scientific heritage and clinical leadership to deliver transformative therapies that change the lives of people with chronic diseases. With a focus on hematology, oncology, and autoimmune diseases, we are advancing a proven foundation while embracing next-generation technologies to redefine what’s possible in biopharma.

Vision

PharmaEssentia stands at a pivotal moment—honoring the legacy of scientific rigor and patient impact that brought us here, while pioneering the frontier of innovation for the decades ahead. Our vision is to be a global leader that not only delivers best-in-class therapies, but also champions the application of frontier technologies to create a new paradigm in medicine.


We see ourselves as a bridge between the traditions of excellence that define established pharma and the bold future shaped by science and technology. By integrating deep medical expertise with cutting-edge innovation, we aim to lead the next era of biopharma, from Asia to the world.